The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus
Open accessAbstract
Background The recently published UK guidelines for the management of SLE recommend biologic therapy for severe or refractory disease. The British Isles Lupus Assessment Group Biologics Register (BILAG-BR) has shown rituximab (RTX) to be safe, effective and corticosteroid [CS] sparing when used to treat refractory SLE. In 2013 NHS England published an interim clinical commissioning policy statement with criteria determining when RTX can be used to treat SLE. Objectives We evaluated our centre’s RTX retreatment strategy in patients with SLE and the consequent outcomes (disease activity and CS dose). Methods Records for the first 50 patients receiving RTX for refractory SLE who consented to join BILAG-BR from our centre between December 2013 and January 2016 were analysed (data cut off July 2016). Demographics, disease activityBILAG 2004/SLEDAI-2K), change in CS dose, retreatment schedules and adverse events were analysed. Results Median(IQR) age and disease duration were 42.8 (33–53) years and 9.5 (4–15.8) years respectively. Male: female ratio was 1:25. 80% were Caucasian, 6% Asian, 4% Caribbean and 10% other. All patients met SLICC/ACR classification criteria for SLE. The median(IQR) SLEDAI-2K scores and BILAG 2004 scores reduced from 6 (4–8) to 4 (0–4) (p<0.00001) and 20 (10–24.5) to 9 (2–15.5) (p<0.001) respectively at 6 months. Complete response was achieved in 62.8% patients (defined as loss of all BILAG A and B scores to ≤1B score with no new A/B scores in other organ domains). 66% patients lost all A scores at 6 months. Median(IQR) daily CS dose reduced from 10 mg(0–20) to 5 mg(0.5–9.5) at 6 months (P=<0.001) and was 5 mg (0–6.63) at last reported visit (median (IQR) 13 (12–19.5) months). 16 patients did not fully respond to baseline treatment but 11 responded to retreatment. Serious infections (requiring hospital admission) occurred in 6 patients (12%). 30/50 patients received their 1 st course of RTX at BILAG-BR baseline visit. 23 met criteria for active disease (at least 1A or 2Bs), 6 were taking an unacceptably high maintenance CS dose, and 1 was planning pregnancy. Median(IQR) CS dose in this group at baseline was 10 mg(1.5–20), and 5 mg(3–9) at 6 months. 70.8% demonstrated complete response at 6 months. 17 (57%) went on to have retreatment due to active disease, of which 11 (64.7%) had responded at 6 months post retreatment. Median(IQR) time to retreatment was 8 (6–12) months. 20/50 patients had received retreatment at predetermined intervals prior to their baseline BILAG-BR visit. Median(IQR) numbers of previous RTX courses were 3 (2–6). Median(IQR) CS dose was 8.75 mg(0–11.3) at baseline BILAG-BR visit and 5.5 mg(0–10) at 6 months. Median(IQR) time from baseline to retreatment was 6 (6–9.5) months. Median(IQR) sustained response was 18 (13.5–18) months. Conclusions Historically, our centre used time from 1 st treatment to flare as a guide to a patient’s future RTX retreatment schedule; patients were, on average, treated 2 months earlier than those treated under the current commissioning policy. Findings suggest that earlier retreatment led to sustained disease control and reduction of CS dose with no increase in adverse events. 11/16 incomplete responders responded following retreatment. Early retreatment may be associated with better outcomes for the patient and further research is needed in this area. Disclosure of Interest None declared
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070367 · Cited by 762
Cited by
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S.-C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224762 · Cited by 1,081
Self-citationFanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Self-citationSystemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Neutrophil extracellular traps in homeostasis and disease
Wang, H., Kim, S. J., Lei, Y., Wang, S., Wang, H., Huang, H., Zhang, H., & Tsung, A. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01933-x · Cited by 537
Metadata
- Authors
- Kraaij, T., Kamerling, S. W. A., de Rooij, E. N. M., van Daele, P. L. A., Bredewold, O. W., Bakker, J. A., Bajema, I. M., Scherer, H. U., Toes, R. E. M., Huizinga, T. J. W., Rabelink, T. J., van Kooten, C., & Teng, Y. K. O.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 91
- Pages
- 45-54
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2795707233
- Cited by
- 164
- References
- 1
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. https://app.cochat.ai/papers/10.1016/j.jaut.2018.03.003
- The paper
- Kraaij, T., Kamerling, S. W. A., de Rooij, E. N. M., van Daele, P. L. A., Bredewold, O. W., Bakker, J. A., Bajema, I. M., Scherer, H. U., Toes, R. E. M., Huizinga, T. J. W., Rabelink, T. J., van Kooten, C., & Teng, Y. K. O. (2018). The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2018.03.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.